IPI Legacy Liquidation Co

OTCPK:IMPL.Q Stock Report

Market Cap: US$358.5k

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

IPI Legacy Liquidation Co Balance Sheet Health

Financial Health criteria checks 0/6

IPI Legacy Liquidation Co has a total shareholder equity of $-91.9M and total debt of $111.0M, which brings its debt-to-equity ratio to -120.8%. Its total assets and total liabilities are $35.1M and $127.0M respectively.

Key information

-120.78%

Debt to equity ratio

US$111.00m

Debt

Interest coverage ration/a
CashUS$239.00k
Equity-US$91.90m
Total liabilitiesUS$126.98m
Total assetsUS$35.07m

Recent financial health updates

Recent updates

Analysis Article Apr 17

Investors Still Aren't Entirely Convinced By Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Revenues Despite 50% Price Jump

Impel Pharmaceuticals Inc. ( NASDAQ:IMPL ) shareholders are no doubt pleased to see that the share price has bounced...
Analysis Article Mar 30

The Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Full-Year Results Are Out And Analysts Have Published New Forecasts

There's been a notable change in appetite for Impel Pharmaceuticals Inc. ( NASDAQ:IMPL ) shares in the week since its...
Analysis Article Mar 26

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Analysts Just Slashed This Year's Revenue Estimates By 12%

The latest analyst coverage could presage a bad day for Impel Pharmaceuticals Inc. ( NASDAQ:IMPL ), with the analysts...
Seeking Alpha Aug 15

Impel NeuroPharma GAAP EPS of -$1.09 misses by $0.04, revenue of $2.8M misses by $1.04M

Impel NeuroPharma press release (NASDAQ:IMPL): Q2 GAAP EPS of -$1.09 misses by $0.04. Revenue of $2.8M misses by $1.04M.
Seeking Alpha Jul 19

Impel stock rises as dosing begins in mid-stage trial of INP105 for agitation in autistic people

Impel Pharmaceuticals (NASDAQ:IMPL) stock rose ~4% on July 19 after the company said that the first person was dosed in a phase 2a trial of nasal-delivered antipsychotic olanzapine, INP105, for the acute treatment of agitation in people with autism spectrum disorder (ASD). The company noted that it is developing INP105 using its proprietary Precision Olfactory Delivery technology which delivers drugs to the upper nasal space. The study will enroll patients 12 to ˂ 18 years of age with ASD experiencing agitation, who will either receive INP105 or placebo. The main goals of the trial are to evaluate the incidences of adverse events (AEs) and serious AEs in both groups at 48 hours post-dose and overall. Meanwhile, secondary goals are to evaluate the efficacy over two hours with a single dose of INP105 versus placebo on acute agitation in the patients. The company expects results in Q1 2023.
Seeking Alpha Jun 28

Impel Pharmaceuticals: Under The Radar Despite Upside Potential

Impel Pharmaceuticals has slipped under the radar since its IPO back in April of last year. The company has made significant progress with its launch of Trudhesa. Impel continues to see Trudhesa prescription momentum increasing and is confident that it will see growth in both new and refill prescriptions. I believe IMPL is heavily discounted at its current price, especially considering the possibility the company will continue to leverage its POD technology. I'm looking to establish a position in the immediate term and will build that position over the remainder of 2022.

Financial Position Analysis

Short Term Liabilities: IMPL.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: IMPL.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: IMPL.Q has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: IMPL.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMPL.Q has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IMPL.Q has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26.9% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/08 06:48
End of Day Share Price 2024/04/05 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IPI Legacy Liquidation Co is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yatin SunejaGuggenheim Securities, LLC
Dana FlandersGuggenheim Securities, LLC
Kenneth CacciatoreTD Cowen